| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple NCT04081389 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Patho NCT03872388 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Tr NCT04185311 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Ca NCT03644589 | University of Washington | Phase 2 |
| Terminated | Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolle NCT03609021 | Alliance for Clinical Trials in Oncology | — |
| Completed | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast NCT03599453 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer NCT03544125 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Can NCT03213041 | Northwestern University | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Completed | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer NCT03106077 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Br NCT02971761 | City of Hope Medical Center | Phase 2 |
| Unknown | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hor NCT03044730 | Northwestern University | Phase 2 |
| Suspended | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) NCT02993068 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca NCT02957968 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuva NCT02945579 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer NCT02744053 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Brea NCT02876107 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis NCT02774681 | Northwestern University | Phase 2 |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrin NCT02398773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative NCT02648477 | City of Hope Medical Center | Phase 2 |
| Completed | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negat NCT02672475 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating NCT02488967 | NRG Oncology | Phase 3 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple- NCT02411656 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Bre NCT02457910 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer NCT02120469 | City of Hope Medical Center | Phase 1 |
| Terminated | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiv NCT01957514 | University of Washington | — |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01964924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Completed | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01624441 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT01575522 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients Wit NCT01525966 | City of Hope Medical Center | Phase 2 |
| Terminated | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer NCT01319539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Remo NCT01276496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Tr NCT01238133 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer NCT01145430 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Su NCT01071564 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291 | National Cancer Institute (NCI) | Phase 3 |